Search clinical trials for: Dabigatran etexilate tablet D1

Total 127 results

Boehringer Ingelheim

Completed

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Venous Thrombosis | Arthroplasty, Replacement, Knee

Japan
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

Healthy
Nova Scotia Health Authority
Dalhousie University; Université de Montréal; Capital Health, Canada

Completed

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Blood Coagulation Disorders

Canada
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

Renal Insufficiency
Boehringer Ingelheim

Terminated

Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN)

Heart Valve Diseases

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
Boehringer Ingelheim

Terminated

Follow on Study From RE-ALIGN

Thromboembolism | Heart Valve Prosthesis

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland
Boehringer Ingelheim

Completed

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Healthy

Germany
Herlev and Gentofte Hospital
Danish Society of Cardiology

Recruiting

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (DANNOAC-VTE)

Deep Vein Thrombosis | Pulmonary Embolism

Denmark
Herlev and Gentofte Hospital
Danish Society of Cardiology

Recruiting

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (DANNOAC-AF)

Atrial Fibrillation | Atrial Flutter

Denmark
Boehringer Ingelheim

Completed

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Healthy
Ural State Medical University
Boehringer Ingelheim

Unknown

Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study) (RE-SOUND)

Atrial Fibrillation

Russian Federation
Boehringer Ingelheim

Completed

Safety and Tolerability of Dabigatran Etexilate in Adolescents

Venous Thromboembolism

Canada
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Capsule Types of Dabigatran

Healthy

Germany
Boehringer Ingelheim

Terminated

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

Stroke | Atrial Fibrillation

United States, Denmark, Netherlands, Sweden
Irina Ermolaeva

Recruiting

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD (RE-ELECT)

Chronic Kidney Diseases | Atrial Fibrillation | T2DM (Type 2 Diabetes Mellitus)

Russian Federation
Boehringer Ingelheim

Completed

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Venous Thromboembolism | Secondary Prevention

United States, Norway, Canada, Belgium, Thailand, Italy, Germany, Turkey, Austria, Hungary, Czechia, Taiwan, Israel, Brazil, Denmark, France, Lithuania, Mexico, Russian Federation, Sweden, Switzerland, Ukraine
Boehringer Ingelheim

Completed

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Renal Insufficiency, Chronic

Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Cardiovascular Diseases | Kidney Failure, Chronic

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

Healthy

Germany
Capital Medical University

Unknown

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Cerebral Venous Thrombosis

China
Boehringer Ingelheim

Withdrawn

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Venous Thromboembolism

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Healthy

Germany
The Affiliated Hospital Of Guizhou Medical University

Not yet recruiting

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Hepatic Insufficiency
Boehringer Ingelheim

Completed

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Thromboembolism

Spain, Germany, India, Italy, Netherlands, Portugal, France, Poland, Russian Federation
Boehringer Ingelheim

Completed

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Healthy

Japan
Dongyang Liu

Recruiting

Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects

Health, Subjective | Nonvalvular Atrial Fibrillation

China
The University of Hong Kong

Recruiting

Dabigatran for Mitral Stenosis Atrial Fibrillation

Atrial Fibrillation | Mitral Stenosis

Hong Kong
Bayer

Completed

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Boehringer Ingelheim

Completed

Japanese Pradaxa PMS, Long Term

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Atrial Fibrillation

Taiwan
Boehringer Ingelheim

Completed

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Venous Thromboembolism

Italy, Thailand, Russian Federation, Canada, Lithuania, Switzerland
Boehringer Ingelheim

Completed

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Atrial Fibrillation

Japan
Boehringer Ingelheim

Recruiting

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot (DaPaR)

Venous Thromboembolism

Spain, Germany, Netherlands, Czechia, Finland, Sweden
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
Intermountain Health Care, Inc.
Boehringer Ingelheim

Completed

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)

Dementia | Cognition Disorders | Cerebral Ischemic Events

United States
Medical University of South Carolina
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Interstitial Lung Disease | Scleroderma

United States
Research Institute for Complex Problems of Cardiovascular...

Unknown

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

Atrial Fibrillation | Mitral Valve Stenosis and Insufficiency

Russian Federation
Meshalkin Research Institute of Pathology of Circulation

Unknown

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy (Re-Spire)

Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Russian Federation
AstraZeneca
Eli Lilly and Company

Completed

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States
Boehringer Ingelheim

Completed

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Atrial Fibrillation

Korea, Republic of
Vanderbilt University Medical Center
Boehringer Ingelheim

Completed

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

Atrial Fibrillation | Atrial Flutter

United States
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Stroke | Secondary Prevention

Korea, Republic of, United States, Spain, Canada, Germany, Taiwan, Belgium, Australia, Hong Kong, India, Singapore, Thailand, Greece, Italy, Japan, China, Turkey, Russian Federation, Serbia, Switzerland, Israel, South Africa, Malaysia, Fran... and more

3

Subscribe